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Papillary-cystic neoplasms of the middle ear are distinct from endolymphatic sac tumours
Aims: Papillary neoplasms of the middle and inner
ear are rare and poorly characterised. The current
World Health Organization classification divides them
into two major subtypes: aggressive papillary
tumours (APTs) and endolymphatic sac tumours
(ELSTs). The aim of this article is to present two pap-
illary neoplasms of the middle ear that do not fit into
either the classic APT category or the classic ELST
category, and compare them with three ELSTs.
Methods and results: The patients were a 48-year-old
female and a 59-year-old male without a history of
other neoplasms. Histology showed papillary-cystic
growth of predominantly oncocytic (Case 1) or muci-
nous (Case 2) cells surrounded by a p63-positive basal
layer. The overall histology was reminiscent of onco-
cytic sinonasal papilloma (Case 1) and pancreatobiliary
or salivary intraductal papillary mucinous neoplasms
(Case 2). Ovarian-type stroma, invasion and malignant
features were absent. Immunohistochemistry revealed
expression of cytokeratin (CK) 7, but not carbonic
anhydrase IX (CAIX) or paired box gene 8 (PAX8) (ex-
cept for very focal PAX8 expression in Case 1). The
TST15 gene panel and HRAS sequencing revealed no
pathogenic mutations in BRAF, KRAS, EGFR, AKT1, or
HRAS. The TruSight RNA fusion panel revealed an
MKRN1–BRAF fusion in Case 1. No fusion was
detected in Case 2. The three ELSTs showed classic fea-
tures of the entity, expressed CK7, epithelial membrane
antigen, PAX8, and CAIX, and lacked a basal cell layer.
Conclusion: These novel cases suggest that papillary
tumours of the ear represent a heterogeneous spec-
trum of distinct neoplasms unified by a prominent
papillary-cystic pattern rather than a single entity.
Future studies should clarify whether the MKRN1–
BRAF fusion is a defining recurrent driver event,
especially in those cases reported as sinonasal-type
middle ear papillomas.
Keywords: aggressive papillary tumour, BRAF, ear, endolymphatic sac tumour, IPMN, oncocytic, papillary
mucinous neoplasms, Schneiderian papilloma
Introduction
Papillary neoplasms of the middle and inner ear are
rare. Because of their overlapping clinicopathological
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and imaging characteristics, they are included in a
single chapter in the 2017 4th edition of the World
Health Organization (WHO) classification of head and
neck tumours.1,2 The WHO classification defines two
categories of papillary tumour: aggressive papillary
tumours (APTs)1 and endolymphatic sac tumours
(ELSTs).2 Both types are locally aggressive low-grade
lesions, composed of a single or double layer of bland
columnar to cuboidal cells arranged in a papillary
architecture. Immunohistochemistry (IHC) shows
expression of pan-cytokeratin (CK), CK7, epithelial
membrane antigen (EMA) (100% of cases), and
paired box gene 8 (PAX8) (85% of cases), and nega-
tive staining for CDX2, CK20, and S100.1–4 The diag-
nosis is based on a set of clinicopathological features
and the exclusion of metastasis from more common
papillary tumours of thyroid, pulmonary, renal and
gastrointestinal origin.1–4
Some APTs and ELSTs are associated with von
Hippel–Lindau (vHL) disease.1,2,5–8 Germline VHL
mutations are detectable in 39% of apparently spo-
radic cases, indicating initial manifestation of the
syndrome.8 In addition to molecular homology (both
are predominantly driven by VHL defects), ELST and
clear cell renal cell carcinoma express PAX8 and
CAIX.4
We herein describe two rare variants of papillary
middle ear tumour, one of them resembling oncocytic
sinonasal papillomas and another one composed
entirely of mucinous cells lacking ovarian-type
stroma, mimicking salivary intraductal papillary
mucinous neoplasms (IPMNs).9 For comparison, three
ELSTs are included. In addition to performing clinico-
pathological studies, we investigated the non-ELST
tumours for mutations and gene fusions that are
commonly encountered in comparable salivary or
sinonasal tumours.
Materials and methods
The five cases were identified in our routine and con-
sultation files. The clinicopathological features are
summarised in Table 1. One ELST has been previ-
ously reported.7 Samples were used in accordance
with ethical guidelines for the use of retrospective tis-
sue samples provided by the local ethics committee of
the Friedrich-Alexander University Erlangen-Nurem-
berg (ethics committee statements 24 January 2005
and 18 January 2012). IHC was performed on 3-µm
sections cut from paraffin blocks with a fully auto-
mated system (Benchmark XT System; Ventana Medi-
cal Systems, Tucson, AZ, USA). Details of antibodies
are summarised in Table 2.
M O L E C U L A R S T U D I E S
Tumour DNA isolation from formalin-fixed paraffin-
embedded (FFPE) tumour tissue, amplicon-based mas-
sive parallel sequencing with the TST15 panel (Illu-
mina, San Diego, CA, USA) and HRAS hotspot
(codons 12, 13, and 61) mutation analysis were per-
formed as described previously.10,11
RNA isolated from FFPE tissue was analysed by use
of the TruSight RNA Fusion panel (Illumina) as
described previously.12
Fluorescence in-situ hybridisation (FISH) was per-
formed with the ZytoLight SPEC BRAF Dual Color
Break Apart Probe, which is designed to detect
Table 1. Clinicopathological data of endolymphatic sac tumours (ELSTs) and non-ELST papillary neoplasms








48/F Tympanic cavity 10 9 8 Oncocytic-type
papillary tumour






16 9 105 Mucinous-type
papillary tumour




ELST: Case 1 39/M Endolymphatic sac 18 9 8 ELST Complete surgical excision Two recurrences:
NED (36)
ELST: Case 2 27/F Petrous bone 28 9 14 ELST Complete surgical excision NED (15)
ELST: Case 3 69/M Endolymphatic sac 17 9 10 ELST – NED (5)
F, Female; M, Male; NED, No evidence of disease.
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rearrangements involving the 7q34 locus harbouring
BRAF (ZytoVision, Bremerhaven, Germany). Amplifi-
cation of the epidermal growth factor receptor (EGFR)
gene (at 7p11.2) was assessed with a ZytoLight SPEC
EGFR/CEN 7 Dual Color Probe (ZytoVision). All
assays were performed according to the manufac-
turer’s instructions.
Results
C L I N I C A L F E A T U R E S O F P A P I L L A R Y - C Y S T I C
N E O P L A S M S O F T H E M I D D L E E A R
Case 1
A 48-year-old woman presented with chronic catar-
rhal otitis and a persistent sensation of a plugged
right ear. The audiogram showed conductive hearing
loss of 20–30 dB and a type B tympanogram. On
clinical examination, the tympanic membrane
appeared to be everted. At surgery, mucinous mate-
rial mixed with granulation tissue was found in the
tympanic cavity. The patient had no previous or con-
current neoplasms. The patient was free of disease at
last follow-up (56 months). Genetic workup revealed
no evidence of vHL disease.
Case 2
A 59-year-old man presented with a 4-month his-
tory of left facial nerve palsy (House Brackmann
grade IV–V13) and a 2-month history of otorrhea
associated with microperforation of the tympanic
membrane. He had no history of other malignancies
or evidence of another primary tumour. The audio-
gram showed conductive hearing loss of 40 dB, and
a type B tympanogram. Preoperative computed
tomography (CT) revealed diffuse opacity of the mas-
toid bone. The patient underwent canal wall down
mastoidectomy. Mucinous material was found in
mastoid cells and in the middle ear without temporal
bone erosion or invasion of the middle ear struc-
tures. Positron emission tomography examination
4 months later showed limited persistent disease in
the temporal bone, justifying subtotal petrosectomy.
There was no evidence of recurrence at last follow-
up (25 months). Genetic workup revealed no evi-
dence of vHL disease.
Table 2. Antibodies employed in the immunohistochemical study
Antibody Clone and provider Species and dilution Antigen retrieval
CK7 OV-TL; Biogenex, Fremont, CA, USA Mouse, 1:1000 CC1
p63 SS16; DCS, Hamburg, Germany Mouse, 1:100 CC1
S100 Polyclonal; Dako, Glostrup, Denmark Mouse, 1:2500 CC1
AR AR441; Dako, Glostrup, Denmark Mouse, 1:50 CC1
MUC1/EMA E29; Dako, Glostrup, Denmark Mouse, 1:20 CC1
MUC2 CCP58; Dako, Glostrup, Denmark Mouse, 1:50 CC1
MUC4 8G7; Santa Cruz, Heidelberg, Germany Mouse, 1:500 CC1
MUC5AC MRQ19; CellMarque, Rocklin CA, USA Mouse, 1:200 CC1
MUC6 MRQ20; CellMarque, Rocklin, CA, USA Mouse, 1:200 CC1
CK20 Ks20.8; Dako, Glostrup, Denmark Mouse, 1:50 CC1
CDX2 CDX2-88; DCS, Hamburg, Germany Mouse, 1:50 CC1
PAX8 Polyclonal; CellMarque, Rocklin, CA, USA Mouse, 1:50 CC1
TTF1 8G7G3/1; Zytomed Systems, Berlin, Germany Mouse, 1:500 CC1
CAIX Polyclonal; Abcam, Cambridge, UK Mouse, 1:1000 CC1
EGFR 3C6; Vantana Roche, Monza, Italy Mouse, prediluted CC1
AR, Androgen receptor; CAIX, Carbonic anhydrase IX; CK, Cytokeratin; EGFR, Epidermal growth factor receptor; EMA, Epithelial membrane
antigen; MUC, Mucin; PAX8, Paired box gene 8; TTF1, Thyroid transcription factor 1.
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P A T H O L O G I C A L F I N D I N G S O F P A P I L L A R Y - C Y S T I C
N E O P L A S M S O F T H E M I D D L E E A R
Case 1 showed exophytic and endophytic growth of
linear and complex branching papillae covered by
multiple layers of columnar cells with abundant eosi-
nophilic granular cytoplasm and vesicular to hyper-
chromatic nuclei. Scattered mucinous cells with
basally oriented nuclei were seen. There were intraep-
ithelial microcysts filled with mucinous material and
neutrophils reminiscent of sinonasal papilloma. Peri-
odic acid–Schiff with diastase predigestion (PAS-D)
stain confirmed intracytoplasmic mucin in the scat-
tered mucinous cells. Immunohistochemically, both
cell types expressed CK7 and were negative for CDX2,
CK20, S100, thyroid transcription factor 1 (TTF1),
mucin (MUC) 2, MUC6, carbonic anhydrase IX
(CAIX), EGFR, and androgen receptor (AR). The
oncocytic component stained focally for PAX8,
MUC1, and MUC4, whereas only a few scattered
mucinous cells were positive for these markers.
MUC5AC stained the mucinous but not the oncocytic
cells. Representative images are shown in Figure 1.
Case 2 showed prominent papillae lined by a single,
partially pseudostratified layer of tall columnar
epithelial cells with hyperchromatic, basally oriented
nuclei and pale eosinophilic to clear mucin-contain-
ing apical cytoplasm (PAS-D). A small cholesteatoma
was seen at the periphery. The neoplastic cells dif-
fusely expressed CK7 and EGFR, and were negative
for S100, AR, PAX8, CAIX, CDX2, CK20, and TTF1.
p63 staining demonstrated an incomplete basal layer.
MUC1, MUC2, MUC4, MUC5AC and MUC6 were
immunohistochemically negative. The immunohisto-
chemical results are summarised in Table 3, and rep-
resentative histological and immunohistochemical
images are shown in Figure 2.
M O L E C U L A R F I N D I N G S O F P A P I L L A R Y - C Y S T I C
N E O P L A S M S O F T H E M I D D L E E A R
No mutations were detected in KRAS, AKT1, or
EGFR, which are often mutated, respectively, in pan-
creatic IPMN14,15 and oncocytic and inverted sinona-
sal papillomas,16 salivary gland IPMN,17 and
papillary lesions of the ear in a murine model.18 Also,
no HRAS mutations were found.9
The next-generation sequencing (NGS) RNA fusion
analysis revealed an MKRN1–BRAF fusion in Case 1,
in which exons 1–3 (NM_013446) of MKRN1 were
fused to exon 10 (NM_001354609) of BRAF (Fig-








variant) was composed of an




oncocytic cells with scattered
mucinous elements (A,B). A
prominent villous pattern was
seen focally (C). Microlumina
reminiscent of sinonasal
papilloma are seen (D). At
higher magnification, the
oncocytic pattern is seen; note
the lack of significant atypia or
mitotic activity (E). A
continuous basal layer is
highlighted by p63
immunostaining (F).
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507 genes included in the panel. FISH testing
revealed no BRAF translocation signals. FISH showed
no EGFR amplification in either of the two cases.
C L I N I C A L F E A T U R E S O F E L S T S
Case 1
A 39-year-old male presented with vertigo in 2009
and hearing loss in 2012. Magnetic resonance
tomography (MRT) showed a lesion within the poste-
rior semicircular canal measuring 18 9 8 mm.
Transmastoidal excision was performed, and a diag-
nosis of ELST was made. The patient underwent sur-
gical excision of two recurrences (2014 to 2017).
Since then, he has remained free of disease until
now. Genetic counselling ruled out vHL syndrome.
Case 2
A 27-year-old woman presented in 2012 with right-
sided tinnitus and hearing loss, followed by occa-
sional vertigo 3 years later. In 2018, CT showed a
petrous bone lesion, measuring 28 9 14 mm. Surgi-
cal excision and histopathology confirmed ELST. The
patient remained disease-free 15 months after sur-
gery. There was no clinical evidence of vHL disease.
Case 3
A 69-year-old male with a 30-year history of hearing
loss in the right ear presented with right post-auricu-
lar swelling in 2018. MRT showed an inner ear
lesion invading the internal acoustic meatus and
cerebellum, measuring 17 9 10 mm. Surgical exci-
sion was performed, and ELST was confirmed. The
patient had no recurrence at 5 months. There was
no clinical evidence of vHL disease.
P A T H O L O G I C A L F I N D I N G S O F E L S T S
The three ELSTs showed similar histological and
immunohistochemical findings. They were composed
of simple papillae with oedematous fibrovascular
cores covered by a single or double layer of bland
columnar to cuboidal cells with eosinophilic to clear
cytoplasm and central small, round nuclei. Atypia
and mitoses were absent. The cells expressed CK7,
PAX8, CAIX, EMA (MUC1), and EGFR, and were neg-
ative for CDX2, CK20, S100, TTF1, AR, and p63.
Mucin IHC revealed focal apical positivity for
MUC5AC in Cases 2 and 3, and for MUC6 in Case 3.
No p63-positive basal cell layer was noted. The
immunohistochemical results are summarised in
Table 3. Immunohistochemical results
Antibody Papillary cystic tumour: Case 1 Papillary cystic tumour: Case 2 ELST: Case 1 ELST: Case 2 ELST: Case 3
CK7 + + + + +
p63 + Basal + Basal   
S100     
AR     
MUC1/EMA Focal in oncocytic cells  + + +
MUC2     
MUC4 Focal in oncocytic cells    
MUC5AC Focal in mucinous cells   Focal Focal
MUC6     Focal
CK20     
CDX2     
PAX8 Focal  + + +
TTF1     
CAIX   + + +
EGFR  + + + +
AR, Androgen receptor; CAIX, Carbonic anhydrase IX; CK, Cytokeratin; ELST, Endolymphatic sac tumour; EGFR, Epidermal growth factor
receptor; EMA, Epithelial membrane antigen; MUC, Mucin; PAX8, Paired box gene 8; TTF1, Thyroid transcription factor 1.
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Table 3, and representative images are shown in Fig-
ure 4.
Discussion
The histogenesis and nomenclature of papillary
tumours of the middle and inner ear have been
controversial. In 1988, Gaffey et al.19 reported 10
locally aggressive papillary middle ear tumours, and
this was followed by single cases and small series.20–
28 An endolymphatic sac origin was suggested by
Michaels et al.25 in 1987, and verified in a large ser-
ies (n = 20) by Heffner29 in 1990. The endolym-
phatic sac origin was supported by others.30
A B
C D
Figure 2. Case 2 of the non-endolymphatic sac tumour papillary tumours (purely mucinous variant) was composed of an admixture of com-
plex branching papillary proliferations (A,B); note cholesteatoma at the upper left in (A). At higher magnification, the neoplastic cells are
large and columnar, and are arranged in a single layer or pseudostratified layers with basally oriented nuclei and mucinous apical cytoplasm
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Figure 3. Integrated Genome Viewer split-screen view of read alignments of the identified MKRN1–BRAF fusion event in case 1. Shown are
the breakpoints in the MKRN1 locus (left) and the BRAF locus (right), respectively. Alignments whose mate pairs are mapped to the fusion
sequence on the other chromosome are colour-coded. The green-coloured alignments on the left side and on the right side are mate pairs,
illustrating the fusion event. The multicoloured alignments are split reads. All other alignments are coloured grey.
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Subsequent reports, however, generated a continuous
debate regarding the origin and histogenesis of
APTs.31–33 A subset of cases were confined to the
middle ear, suggesting a dual histogenetic theory:
endolymphatic sac and middle ear mucosa.34
Our two cases showed morphological and immuno-
histochemical differences from classic APT and ELST,
but they also differed from each other. Case 1 showed
histological and immunohistochemical features (the
presence of a p63-positive basal layer and the lack of
homogeneous CAIX and PAX8 reactivity) that are
not seen in classic ELST or APT. Instead, its morphol-
ogy was reminiscent of oncocytic IPMN of the pan-
creas and oncocytic sinonasal papilloma.14–16,35–37
The majority of previously reported sinonasal-type
papillomas of the middle ear/temporal bone repre-
sented either genuine squamous papillomas/papillary
squamous carcinomas38 or extension from sinonasal
papillomas,39 or lacked histological illustration. Very
few cases seem to be identical to our Case 1, includ-
ing most of the cases reported by Wenig40 (illustrated
in Figures 1 and 4 of that article) and three case
reports.41–43
The lack of EGFR and KRAS mutations in our Case
1, despite its histological similarity to oncocytic sino-
nasal papillomas, suggests a distinct molecular patho-
genesis.16 We detected an MKRN1–BRAF fusion in
this case. The makorin ring finger protein 1 (MKRN1)
encoded by MKRN1 is a co-regulator of transcription
that controls cell cycle arrest and apoptosis.44 Both
MKRN1 and BRAF have been mapped to
chromosome 7q34. The MKRN1–BRAF fusion is rare,
and has been reported only recently in two papillary
thyroid carcinomas,45,46 an anaplastic thyroid carci-
noma cell line,47 and EGFR-mutant metastatic non-
small-cell lung carcinoma resistant to osimertinib.48
Its fusion product probably leads to constitutive acti-
vation of the kinase.47 Although sufficient tumour
tissue was not available for validation studies, the
negative FISH result can be explained by the close
proximity of the two genes on chromosome 7q34,
which makes the FISH method suboptimal for detec-
tion of the translocation. The absence of additional
genetic alterations in this tumour suggests MKRN1–
BRAF fusion as its driver.
Case 2 has similarities to gastric-type pancreatic
IPMN and the recently described minor salivary gland
IPMN.17 Ovarian-type stroma was absent, ruling out
mixed epithelial and stromal tumour, of which only a
single case has been reported in the middle ear.49
Furthermore, the uniformly mucinous-type epithe-
lium and lack of AR and S100 immunoreactivity
exclude salivary intraductal carcinoma of the apoc-
rine and the intercalated duct type, respectively.50
Also, the lack of NCOA4–RET and TRIM27–RET
fusions as shown by NGS represents another argu-
ment against this possibility.50
Pancreatic and salivary IPMNs harbour KRAS and
AKT1 mutations, respectively.14–16 The AKT1
p.Glu17Lys activating mutation was reported in three
of three17 and eight of nine9 minor salivary gland
IPMNs. A subset of salivary papillary lesions harbour
A B
C D





covered by low-columnar to
cuboidal monomorphic cells
lacking mucinous features or a
basal layer (B). The neoplastic
cells are homogeneously
positive for paired box gene 8
(PAX8) (C) and carbonic
anhydrase IX (CAIX) (D).
© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology
Papillary-cystic ear tumours 7
HRAS mutations.9 Our cases tested negative for
mutations in all of these genes, suggesting a different
molecular pathogenesis.
The development of APTs of the middle ear (similar
to Case 2) in mouse models harbouring mutant EGFR
suggested a role for EGFR.18 Studies on human APTs
and ELST, however, found no EGFR mutations, sug-
gesting different mechanisms.18
In conclusion, this study highlights two putative
novel variants in the spectrum of papillary middle ear
neoplasms: one variant overlapping with oncocytic
sinonasal papilloma, but lacking KRAS mutations
and, instead, harbouring a MKRN1–BRAF fusion;
and another closely mimicking salivary IPMN but
lacking AKT1/HRAS mutations. These tumours
should be separated from ELSTs. Their relationship to
APTs of the middle ear remains to be addressed in
future studies.
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